Alkermes Plc. 10-Q Summary: Q2 2025
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2025. Alkermes Plc. is a global biopharmaceutical company focused on neuroscience, commercializing proprietary products for alcohol dependence, opioid dependence, schizophrenia, and bipolar I disorder. The company also generates revenue through manufacturing and royalty arrangements for third-party products, including long-acting INVEGA products and VUMERITY.
Key Financial Metrics (Six Months Ended June 30, 2025)
- Total Revenues: $697.2 million (Decreased 7.0% vs. prior year).
- Net Income from Continuing Operations: $109.6 million (Decreased 18.0% vs. prior year).
- Diluted EPS (Continuing Ops): $0.65 (Decreased from $0.78 in prior year).
- Operating Cash Flow: $249.0 million (Increased 49.0% vs. prior year).
- Liquidity: Cash and cash equivalents totaled $521.2 million; short-term investments totaled $494.5 million.
- Debt: The company has no outstanding long-term debt as of June 30, 2025, having prepaid term loans in December 2024.
- Effective Tax Rate: 15.9% (Decreased from 18.3% in prior year).
Material Changes vs. Prior Comparable Period
- Revenue Decline: Total revenue decreased primarily due to a $101.3 million drop in manufacturing and royalty revenues. This was driven by the expiration of the royalty on U.S. net sales of INVEGA SUSTENNA in August 2024.
- Product Sales Growth: Net product sales increased by $49.0 million (9.7%) to $551.7 million, driven by a 17% increase in LYBALVI unit sales and a 3% price increase effective January 1, 2025.
- R&D Expenses: Increased by $21.9 million to $149.2 million, largely due to accelerated development of the Alixorexton program (Vibrance studies) and a 10% increase in R&D headcount.
- Cost of Goods Sold: Decreased by $21.4 million, attributed to the sale of the Athlone Facility in May 2024 and lower unit sales of VIVITROL.
- Share Repurchases: No shares were repurchased under the $400 million program during the six months ended June 30, 2025. $200.0 million remains authorized.
Guidance, Outlook, and Risks
- Development Pipeline: Alixorexton achieved its primary endpoint in the Vibrance-1 study for narcolepsy type 1 in July 2025. The company plans to initiate a Phase 3 program.
- Regulatory and Legal:
- VUMERITY: Settled patent litigation with Zydus in July 2025, granting a license for generic entry prior to patent expiration.
- INVEGA TRINZA: The Federal Circuit affirmed the district court's decision in favor of Janssen regarding patent infringement; Mylan Labs filed a petition for rehearing in May 2025.
- Government Investigations: The company is cooperating with subpoenas and civil investigative demands from U.S. authorities regarding VIVITROL.
- Tax Legislation: The "One Big Beautiful Bill" (OBB Bill) signed on July 4, 2025, is expected to materially increase operating cash flows and decrease net U.S. deferred tax assets.
- Trade Risks: New U.S. tariffs announced in April 2025 (baseline 10%) and potential supplemental tariffs on pharmaceutical imports pose risks to supply chain costs and profitability.
Investor Verification Checklist
- Verify the sustainability of the revenue decline in royalty streams from long-acting INVEGA products post-royalty expiration.
- Monitor the timeline and results of the planned Phase 3 program for Alixorexton following the Phase 2 success.
- Assess the financial impact of the VUMERITY settlement and the timing of generic market entry.
- Review the status of government investigations into VIVITROL and potential liability accruals.
- Confirm the impact of new U.S. trade tariffs on international supply chain costs for proprietary products.